Nilotinib is a transduction inhibitor that
targets BCR-ABL, c-kit and PDGF, for the potential treatment of various
leukemias, including chronic myeloid leukemia (CML). Chronic myelogenous leukemia
(CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the
tyrosine kinase activity of the BCR-ABL protein.
Reference
Tripathi K.D.,” Essentials of Medical Pharmacology”, Jaypee
Brothers Medical Publishers (P) LTD, New Delhi, Seventh Edition, Pg No. 870
No comments:
Post a Comment